Moderna, through Takeda, is requesting authorization for the COVID-19 vaccine in Japan

by

Shares of Moderna Inc. MRNA,
-3.64%
fell 0.9% in premarket trading on Friday after the company said it was seeking approval for COVID-19 vaccine in Japan in partnership with Takeda Pharmaceutical Co. 4502,
-0.58%.
Takeda has applied for the drug and will be in charge of importing and distributing the vaccine from the Cambridge, Massachusetts company. Takeda also carries out phase 1/2 of the vaccine in adults who are at least 20 years old there; registration ended in February. If approved, Takeda will distribute 50 million doses of Moderna’s two-dose vaccine to Japan in the first half of 2021. Shares of Moderna have accumulated 372.3% in the last 12 months, while the S&P 500 SPX larger,
+ 0.24%
is increasing by 20.4%.

.Source